BioXcel Therapeutics (BTAI) Retained Earnings (2017 - 2026)

BioXcel Therapeutics' Retained Earnings history runs 10 years deep, the most recent figure standing at -$732.8 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 11.46% year-over-year to -$732.8 million; the TTM figure through Mar 2026 stood at -$732.8 million (down 11.46% YoY), while the FY2025 annual figure was -$720.1 million, down 10.75% from the prior year.
• Retained Earnings was -$732.8 million for Q1 2026 at BioXcel Therapeutics, down from -$720.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$277.3 million in Q1 2022 to a low of -$732.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$560.5 million across 5 years, with a median of -$617.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 67.8% in 2022, then fell 6.49% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$411.5 million in 2022, then plunged by 43.51% to -$590.6 million in 2023, then fell by 10.09% to -$650.2 million in 2024, then declined by 10.75% to -$720.1 million in 2025, then declined by 1.76% to -$732.8 million in 2026.
• The last three Retained Earnings figures came in at -$732.8 million (Q1 2026), -$720.1 million (Q4 2025), and -$707.5 million (Q3 2025), per Business Quant data.